Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.4.24.3 (
collagenase
)
18,340
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
F-box only protein 22
(
FBXO22
), a substrate receptor of the SKP1-Cullin 1-F-box protein (SCF) E3 ubiquitin ligase that targets key regulators of cellular activities for ubiquitylation and degradation, plays important roles in the progression of human cancer. However, little is known about the role of
FBXO22
in renal cell carcinoma (RCC). This study aims to explore the biological function of
FBXO22
in RCC progression and its specific regulation mechanism. We performed immunohistochemistry analysis and found that the expression level of
FBXO22
was significantly lower in RCC tissues than in normal renal tissues. Reduced
FBXO22
expression in RCC tissues is related to tumor size and TNM stage and to worse overall and disease-free survival. Through an
in vitro
assay, we demonstrated that
FBXO22
has no effect on renal cancer cells proliferation, whereas
FBXO22
remarkably restricted RCC cell migration and invasion, thereby reversing EMT transition and elevating the activity of tissue inhibitor of
matrix metalloproteinase-1
, which subsequently inhibited metalloproteinase-9 (MMP-9) expression and activity
in vitro
. We also found that
FBXO22
suppresses tube formation by disrupting the secretion of vascular endothelial growth factor. Meanwhile,
in vivo
studies verified that
FBXO22
suppresses RCC metastasis. These findings suggested that
FBXO22
is a novel prognostic indicator and plays an important role in RCC metastasis.
...
PMID:FBXO22 Suppresses Metastasis in Human Renal Cell Carcinoma via Inhibiting MMP-9-Mediated Migration and Invasion and VEGF-Mediated Angiogenesis. 3074 51